CLINICAL_TRIALS trial_result · 2022-02-10

Clinical Trial Update: A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) [Phase 2]

A Phase 2 study evaluating INCB050465 in relapsed or refractory marginal zone lymphoma has completed, and results were posted on February 10, 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Incyte Corporation | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2022-02-10